Table 1

Effect of treatment with cytotoxic LH-RH analogue AN-152, DOX, or Decapeptyl on the growth of MDA-PCa-2b human androgen sensitive prostate cancer, bodyweights, and WBC counts in nude mice (Exp. II)

Treatment groupsTumor volume (mm3)Tumor doubling time (days)Tumor weight (mg) (% inhibition)Bodyweight (grams)WBC (leukocytes/mm3)
InitialFinal (% Inhibition)
Control86.8 ± 26.21666.9 ± 292.96.7 ± 0.41551.5 ± 249.324.9 ± 0.97216.0 ± 1276.0
Decapeptyl84.6 ± 9.91278.9 ± 335.4 (23%)8.4 ± 1.21497.3 ± 371.1.0 (3%)24.8 ± 0.87608.3 ± 1503.0
DOX84.4 ± 17.91134.8 ± 214.1 (32%)8.3 ± 1.11291.8 ± 243.6 (17%)23.3 ± 1.68231.7 ± 1430.4
AN-15284.2 ± 19.4520.1 ± 65.1 (69%)a,b12.4 ± 1.1a,b564.4 ± 88.2 (64%)a,b24.2 ± 1.18074.0 ± 1323.0
  • a P < 0.01 vs. control.

  • b P < 0.05 vs. Decapeptyl and DOX.